Explore

Trendline Trendline
Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases
Trendline Trendline
Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies for Neurodegenerative Diseases

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies for Neurodegenerative Diseases

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies for Neurodegenerative Diseases
Trendline Trendline
Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies
Trendline Trendline
Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback
Trendline Trendline
Tempus and Bristol Myers Squibb Partner to Enhance Clinical Development in Oncology and Neuroscience

Tempus and Bristol Myers Squibb Partner to Enhance Clinical Development in Oncology and Neuroscience

Tempus and Bristol Myers Squibb Partner to Enhance Clinical Development in Oncology and Neuroscience
Trendline Trendline
Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI
Trendline Trendline
AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics

AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics

AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics
Trendline Trendline
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Trendline Trendline
Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges